{
  "docId": "019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "docSlug": "03e126adc7ca1480",
  "documentTitle": "20250114 bayer handout jpm 2025",
  "authorId": "JPMorgan",
  "authorName": "Bayer",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 11,
  "pageCount": 18,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a bar chart showing sales growth from 2021 to 2024e.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "bar_chart_stacked",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-9cdc5d048fe2/11",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.7,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Perspectives 2025 and beyond\nFurther drive uptake in ~700m patient CKD market, by accelerating CKD/T2D indication and broadening to cover whole spectrum of CKD\nPrepare launch into underserved market, addressing ~50% of HF patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8065a1d5-889d-4572-9732-098b489da9d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Further drive uptake in ~700m patient CKD market, by accelerating CKD/T2D indication and broadening to cover whole spectrum of CKD.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-2301-748f-910f-b2020f974d58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.08,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Global Sales (€bn)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e06b54cd-e974-4b66-ab87-48247cf97aef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.08,
        "y": 0.4
      },
      "kind": "list",
      "text": "Strong growth in CKD/T2D in key regions and countries, driven by US and China\nHF indication offers significant growth potential:\nFINEARTS-HF showed groundbreaking results in highly underserved space\nApplications for HF indication in US and China just submitted",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "951e020a-dc50-40e4-a44c-3aef88db1d32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Global Sales: €0.5bn",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-2301-748f-910f-b5e3d4e20ecb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Kerendia (finerenone) tablets is the only selective, nonsteroidal MRA with proven Heart and Kidney benefit",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd8f6ba5-de97-412f-81be-05cce12482ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.08,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1 MRA = mineralocorticoid receptor antagonist 2 CKD = Chronic Kidney Disease 3 T2D = type-2 Diabetes 4 HF = Heart Failure",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a3f4fc4-ba0f-47da-bb16-a397499cf59d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.08,
        "y": 0.05
      },
      "kind": "title",
      "text": "Kerendia: Building a True Cardiorenal Brand in Chronic Kidney Disease and Heart Failure",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f33044b3-7b0e-4d71-a3ae-9c78e62c2fde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "4fb92e14-cf15-4676-8ce2-492b451ec13d",
      "evidence": "list/bullet: Strong growth in CKD/T2D in key regions and countries, driven by US and China; HF indication offers significant growth potential: FINEARTS-HF showed groundbreaking results in highly underserved space",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "f381b448-fcf0-4030-b26e-c9fd2c74d1c9",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcase the company's market-leading positions and innovation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6ade2762-544e-41aa-adcf-f0724dca9dce",
      "evidence": "The slides highlight the company's 'why', 'what', and 'how'",
      "position": 1,
      "objective": "Why is Bayer's strategic agenda important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}